Alembic Pharma Extends Weekly Decline Amid USFDA Update

closed negative for the second consecutive week ended 20 Feb 2026, with the stock showing subdued momentum. A key development was the USFDA’s unannounced cGMP inspection at the company’s injectable facility (F-3) in Karakhadi during February 9–18. The inspection concluded with two observations, none linked to data integrity. Technically, the stock is in lower lows & lower highs formtaiona and trading below its its 200-day SMA. Friday’s close was around ₹763, third consecutive negative streak. Levels near ₹744 and ₹725 are being tracked as important support zones by market participants, reflecting a crucial area on the charts. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.